Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn

6. Coya Therapeutics, Inc. (NASDAQ:COYA)

Greenlight Capital’s Equity Stakes: $9.43 Million

Number of Hedge Fund Holders: 3

Coya Therapeutics, Inc. (NASDAQ:COYA) is a biotechnology company that develops therapies that enhance the function of regulatory T cells (Tregs) to target systemic and neuroinflammation. Its lead candidate, COYA 302, targets conditions like ALS, FTD, Parkinson’s, and Alzheimer’s. The company boasts of a scientifically sound approach to neurodegenerative illnesses with its strategic focus on neuroinflammation.

It sets itself apart from other businesses with its approach to possible combination medicines for the treatment of neurological illnesses. Additionally, it provides a more effective paradigm for therapy that may open up new possibilities for patients and provide significant value for shareholders. By combining low-dose IL-2 with CTLA4-Ig, its lead candidate, COYA-302, targets a crucial immunological mechanism in dementia, setting it apart from rivals that only target protein aggregation or single molecules.

Coya Therapeutics, Inc. (NASDAQ:COYA) has already reported positive findings from Phase 2 Alzheimer’s disease research and advancements in Frontotemporal Dementia trials. While also making great strides in initiatives related to neurodegenerative disorders with high unmet needs, Coya is steadily growing its medication pipeline. Coya’s capacity to carry out corporate, clinical, and regulatory objectives and keep adding value is reinforced by its solid scientific and clinical justification, solid cash position, and potential for new commercial development prospects.